Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer

Table 4 Univariate subgroups analysis of overall survival

	FOLFOX-4			TOPOTECAN
	No. patients	No. events	Median PFS (95% CI)	No. patients	No. events	Median PFS (95% CI)	P
Site of metastasis
Only abdominal	11	11	5.0 (1.3–14.6)	20	18	10.4 (2.9–25.0)	0.166
Abdominal+extra-abdominal	18	17	8.2 (2.4–16.7)	6	6	12.7 (2.7–23.4)	0.919
P			0.771			0.492
Lines of previous treatments
≤ 4	15	15	10.2 (1.3–16.7)	20	18	10.5 (2.7–25.0)	0.057
> 4	14	13	5.5 (2.4–14.6)	6	6	10.4 (2.9–16.2)	0.789
P			0.753			0.206
Baseline NLR
< 3	13	12	14.6 (3.8–22.9)	20	18	10.4 (4.9–23.4)	0.870
≥ 3	15	15	5.4 (1.2–10.2)	5	5	2.9 (1.5–15.0)	0.858
P			0.013			0.051
Baseline PLR
< 210	13	12	13.0 (1.8–18.9)	18	16	10.5 (4.9–23.3)	0.514
≥ 210	15	15	5.6 (1.3–14.1)	7	7	10.0 (1.5–15.0)	0.660
P			0.275			0.061

Abbreviations. FOLFOX-4 oxaliplatin, leucovorin, and 5-fluorouracil; number; CI confidence interval, NLR neutrophils-to-lymphocyte ratio, OS overall survival, PLR platelet-to-lymphocyte ratio

ISSN: 1471-2407